Manuel Haschke

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. doi [Clinical pharmacological aspects of new oral anticoagulants]
    M Haschke
    Klinische Pharmakologie und Toxikologie, Universitatsspital Basel
    Ther Umsch 69:657-60. 2012
  2. pmc Pharmacokinetics and pharmacodynamics of nasally delivered midazolam
    Manuel Haschke
    Division of Clinical Pharmacology and Toxicology, University of Basel, Basel, Switzerland
    Br J Clin Pharmacol 69:607-16. 2010
  3. pmc Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping
    Bettina Link
    Division of Clinical Pharmacology and Toxicology and Department of Research, University Hospital, Basel, Switzerland
    Br J Clin Pharmacol 66:473-84. 2008
  4. doi Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model
    Daniela Baldoni
    Department of Biomedicine, University Hospital Basel, Basel, Switzerland
    Int J Antimicrob Agents 42:220-5. 2013
  5. doi Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors
    Yvonne Zysset Aschmann
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:130-4. 2008
  6. doi Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam
    Michael Bodmer
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:120-4. 2008
  7. doi Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose
    Michael Bodmer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:553-6. 2008
  8. pmc Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study
    Adrian Derungs
    Division of Clinical Pharmacology and Toxicology, Inselspital Bern, Bern, Switzerland
    Clin Pharmacokinet 55:79-91. 2016
  9. doi Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy
    Lana Nezić
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 4031, Basel, Switzerland
    Eur J Clin Pharmacol 70:829-37. 2014
  10. ncbi Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient
    Michael Bodmer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Nephrol Dial Transplant 22:2366-70. 2007

Collaborators

  • Michael Bodmer
  • Anne B Taegtmeyer
  • Stephan Krahenbuhl
  • Adrian Derungs
  • Massimiliano Donzelli
  • Daniela Baldoni
  • Lana Nezić
  • Yvonne Zysset Aschmann
  • Christoph Noppen
  • Lea S Blaser
  • Réjane Morand
  • Werner Zimmerli
  • Andrej Trampuz
  • Markus Wenk
  • Bettina Link
  • Oliver Kummer
  • Benjamin Berger
  • Pascal Egger
  • Alexandra Tramonti
  • Alexandra E Rätz Bravo
  • Sarah Tschudin-Sutter
  • Maria Giovanna Serratore
  • Marcel Bruggisser
  • Ulrika Furustrand Tafin
  • Alessandra Oliva
  • Eline Angevaare
  • Sandrine Aeppli
  • Zarko Rajacic
  • Nathalie Grignaschi
  • Andrea Azzola
  • Andre Linka
  • Yolanda Brauchli
  • Jurgen Drewe
  • Marten Trendelenburg

Detail Information

Publications17

  1. doi [Clinical pharmacological aspects of new oral anticoagulants]
    M Haschke
    Klinische Pharmakologie und Toxikologie, Universitatsspital Basel
    Ther Umsch 69:657-60. 2012
    ..Experience with long-term use (> 5 years) is limited. Therefore careful clinical monitoring of patients considering co-medication and co-morbidity is necessary to allow safe therapy with the new oral anticoagulants...
  2. pmc Pharmacokinetics and pharmacodynamics of nasally delivered midazolam
    Manuel Haschke
    Division of Clinical Pharmacology and Toxicology, University of Basel, Basel, Switzerland
    Br J Clin Pharmacol 69:607-16. 2010
    ..To investigate the pharmacokinetics and pharmacodynamics of nasal formulations containing midazolam (5-30 mg ml(-1)) complexed with cyclodextrin...
  3. pmc Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping
    Bettina Link
    Division of Clinical Pharmacology and Toxicology and Department of Research, University Hospital, Basel, Switzerland
    Br J Clin Pharmacol 66:473-84. 2008
    ..To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suitable for CYP3A phenotyping...
  4. doi Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model
    Daniela Baldoni
    Department of Biomedicine, University Hospital Basel, Basel, Switzerland
    Int J Antimicrob Agents 42:220-5. 2013
    ..Dalbavancin at 80 mg/kg and in combination with rifampicin eradicated approximately one-third of cage-associated MRSA infections and prevented emergence of rifampicin resistance...
  5. doi Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors
    Yvonne Zysset Aschmann
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:130-4. 2008
    ..Patients treated concomitantly with protease inhibitors and sildenafil need close monitoring of plasma levels, pharmacodynamics, and toxicity of sildenafil in order to be treated optimally...
  6. doi Pharmacokinetics of midazolam and metabolites in a patient with refractory status epilepticus treated with extraordinary doses of midazolam
    Michael Bodmer
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:120-4. 2008
    ..Even in patients with hepatic CYP3A induction, the half-life of MDZ increases with high doses as a result of a rise in its volume of distribution, which is a consequence of an increase in the free fraction of MDZ...
  7. doi Pharmacokinetics and pharmacodynamics of quetiapine in a patient with a massive overdose
    Michael Bodmer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Ther Drug Monit 30:553-6. 2008
    ..The final elimination of the drug from the body occurred after approximately 34 hours at much slower rate, most probably reflecting redistribution from tissues into blood and consecutive hepatic clearance of the drug...
  8. pmc Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study
    Adrian Derungs
    Division of Clinical Pharmacology and Toxicology, Inselspital Bern, Bern, Switzerland
    Clin Pharmacokinet 55:79-91. 2016
    ..The objective of this study was to characterize the phenotyping metrics of the Basel cocktail in healthy male subjects with induced and inhibited CYP activity...
  9. doi Therapeutic drug monitoring of once daily aminoglycoside dosing: comparison of two methods and investigation of the optimal blood sampling strategy
    Lana Nezić
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 4031, Basel, Switzerland
    Eur J Clin Pharmacol 70:829-37. 2014
    ..We performed a PK study in order to compare both methods and to determine the best time-points to estimate AUC0-24 and peak concentrations (C max)...
  10. ncbi Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient
    Michael Bodmer
    Department of Clinical Pharmacology and Toxicology, University Hospital Basel, Switzerland
    Nephrol Dial Transplant 22:2366-70. 2007
  11. doi The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots
    Massimiliano Donzelli
    Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University of Basel, Basel, Switzerland
    Clin Pharmacokinet 53:271-82. 2014
    ....
  12. pmc A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls
    Anne B Taegtmeyer
    Division of Clinical Pharmacology and Toxicology, University and University Hospital Basel, Basel, Switzerland
    PLoS ONE 9:e97885. 2014
    ..73, n = 18). The bioavailability of and exposure to oral propranolol are increased in patients with cirrhosis. Fasting serum bile acid concentration may be helpful in predicting the exposure to oral propranolol in these patients. ..
  13. doi Hematological safety of metamizole: retrospective analysis of WHO and Swiss spontaneous safety reports
    Lea S Blaser
    Division of Clinical Pharmacology and Toxicology, University Hospital, Hebelstrasse 2, 4031, Basel, Switzerland
    Eur J Clin Pharmacol 71:209-17. 2015
    ..Since the 1970s, the use of metamizole is controversial due to the risk of agranulocytosis. The aim of this study was to analyze individual case safety reports (ICSRs) of metamizole-associated hematological adverse drug reactions (ADRs)...
  14. doi Quantification of plasma carnitine and acylcarnitines by high-performance liquid chromatography-tandem mass spectrometry using online solid-phase extraction
    Réjane Morand
    Clinical Pharmacology and Toxicology, University Hospital Basel, Spitalstrasse 21 Petersgraben 4, 4031, Basel, Switzerland
    Anal Bioanal Chem 405:8829-36. 2013
    ..The method is useful for applications in research and clinical routine...
  15. doi Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects
    Manuel Haschke
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 4031, Basel, Switzerland
    Clin Pharmacokinet 52:783-92. 2013
    ..As a first step we performed a first-in-man study to determine pharmacokinetics, pharmacodynamics, safety, and tolerability of recombinant ACE2 in healthy volunteers...
  16. pmc Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection
    Daniela Baldoni
    Department of Biomedicine, Infectious Diseases Research Laboratory, University Hospital Basel, Basel, Switzerland
    Antimicrob Agents Chemother 53:1142-8. 2009
    ..The linezolid-rifampin combination is a treatment option for implant-associated infections caused by quinolone-resistant MRSA...
  17. ncbi Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage
    Stephan Krahenbuhl
    Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland
    Digestion 75:232-7. 2007
    ..The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated...